These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 26044977)
21. The tachykinergic system as avenues for drug intervention. Rameshwar P Recent Pat CNS Drug Discov; 2012 Aug; 7(2):173-80. PubMed ID: 22472024 [TBL] [Abstract][Full Text] [Related]
22. Bioactive analogs of neurotensin: focus on CNS effects. Boules M; Fredrickson P; Richelson E Peptides; 2006 Oct; 27(10):2523-33. PubMed ID: 16882457 [TBL] [Abstract][Full Text] [Related]
23. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Richelson E; Boules M; Fredrickson P Life Sci; 2003 Jun; 73(6):679-90. PubMed ID: 12801589 [TBL] [Abstract][Full Text] [Related]
24. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Sharma RP; Janicak PG; Bissette G; Nemeroff CB Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757 [TBL] [Abstract][Full Text] [Related]
25. Tachykinins: role in human gastrointestinal tract physiology and pathology. Improta G; Broccardo M Curr Drug Targets; 2006 Aug; 7(8):1021-9. PubMed ID: 16918330 [TBL] [Abstract][Full Text] [Related]
26. Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions. Rostene W; Azzi M; Boudin H; Lepee I; Souaze F; Mendez-Ubach M; Betancur C; Gully D Ann N Y Acad Sci; 1997 Apr; 814():125-41. PubMed ID: 9160965 [No Abstract] [Full Text] [Related]
27. Neurotensin: role in psychiatric and neurological diseases. Cáceda R; Kinkead B; Nemeroff CB Peptides; 2006 Oct; 27(10):2385-404. PubMed ID: 16891042 [TBL] [Abstract][Full Text] [Related]
28. Involvement of neuropeptide systems in schizophrenia: human studies. Cáceda R; Kinkead B; Nemeroff CB Int Rev Neurobiol; 2007; 78():327-76. PubMed ID: 17349866 [TBL] [Abstract][Full Text] [Related]
29. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Joos GF; De Swert KO; Pauwels RA Eur J Pharmacol; 2001 Oct; 429(1-3):239-50. PubMed ID: 11698044 [TBL] [Abstract][Full Text] [Related]
30. Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat. Magraner J; Pinto FM; Anselmi E; Hernandez M; Perez-Afonso R; Martín JD; Advenier C; Candenas ML Br J Pharmacol; 1998 Jan; 123(2):259-68. PubMed ID: 9489614 [TBL] [Abstract][Full Text] [Related]
32. Neurotensin-dopamine interactions: relevance to schizophrenia and the action of antipsychotic drugs. Stowe ZN; Bissette G; Nemeroff CB Yakubutsu Seishin Kodo; 1991 Feb; 11(1):49-59. PubMed ID: 1679273 [TBL] [Abstract][Full Text] [Related]
33. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs? Cáceda R; Kinkead B; Nemeroff CB Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409 [TBL] [Abstract][Full Text] [Related]
34. Neurotensin agonists as an alternative to antipsychotics. Boules M; Fredrickson P; Richelson E Expert Opin Investig Drugs; 2005 Apr; 14(4):359-69. PubMed ID: 15882113 [TBL] [Abstract][Full Text] [Related]
35. Progress in the development of neurokinin 3 modulators for the treatment of schizophrenia: molecule development and clinical progress. Dawson LA; Porter RA Future Med Chem; 2013 Sep; 5(13):1525-46. PubMed ID: 24024945 [TBL] [Abstract][Full Text] [Related]
38. Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia. Nikiforuk A Curr Pharm Des; 2016; 22(14):2093-116. PubMed ID: 26818861 [TBL] [Abstract][Full Text] [Related]
39. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct. Patacchini R; Barthó L; Maggi CA Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808 [TBL] [Abstract][Full Text] [Related]